Related Experiment Videos
Interleukin-6: a new therapeutic target.
Josef S Smolen1, Ravinder N Maini
1Division of Rheumatology, Medical University of Vienna, Vienna, Austria. josef.smolen@wienkav.at
Arthritis Research & Therapy
|August 11, 2006
Summary
Tocilizumab, an anti-interleukin-6 (IL-6) receptor antibody, shows significant therapeutic response rates in rheumatoid arthritis patients. This biologic agent offers a new treatment option for those unresponsive to other therapies.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Tumor necrosis factor (TNF) inhibitors have improved rheumatoid arthritis (RA) treatment, but over 50% of patients show inadequate response.
- Alternative biologics like rituximab and abatacept have limited efficacy and rarely induce remission.
- Interleukin-6 (IL-6) is a key pro-inflammatory cytokine involved in RA pathogenesis and osteoclastogenesis.
Purpose of the Study:
- To review recent phase II clinical trials of tocilizumab, an anti-IL-6 receptor antibody.
- To evaluate the therapeutic efficacy of tocilizumab in rheumatoid arthritis patients.
Main Methods:
- Review of phase II clinical trial data for tocilizumab.
- Analysis of treatment response rates in rheumatoid arthritis patients.
Main Results:
- Tocilizumab demonstrated significant therapeutic response rates in patients with rheumatoid arthritis.
- The anti-IL-6 receptor antibody achieved notable efficacy, suggesting a promising treatment avenue.
Conclusions:
- Tocilizumab represents a significant advancement in rheumatoid arthritis therapy.
- Targeting the IL-6 pathway with tocilizumab offers a viable option for patients with inadequate response to existing treatments.